Individual results during month one vary based on starting weight, baseline metabolism, and how quickly your body responds to GLP-1 receptor activation
Large cardiovascular outcome trials with liraglutide [40], semaglutide [41], and dulaglutide [42] have shown reductions in adverse cardiovascular events and cardiovascular mortality, while the SELECT trial demonstrated a reduction in heart failure with semaglutide [43]
Why should employers care
Suchonwanit, P., Thammarucha, S., & Leerunyakul, K
The evaluated GLP-1RAs were semaglutide (IC 025 = 2.13), liraglutide (IC 025 = 1.18), dulaglutide (IC 025 = 3.76), exenatide (IC 025 = 3.52), and albiglutide (IC 025 = 3.91), none of which exhibited a signal of disproportionate reporting
They can order labs like thyroid function and electrolytes, and consider ambulatory monitoring such as a 24 or 48-hour Holter if symptoms recur